Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

NCT05956821 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT05956821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05956821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Lead sponsor
University of Miami
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 19, 2025
Completion date
December 1, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, diffuse intrinsic brainstem glioma, diffuse intrinsic pontine glioma, dipg brain tumor, fibrillary astrocytomas, glioblastoma multiforme, h3 k27m, oligodendroglioma